Anne-Kathrin Garz
Klinikum rechts der Isar(DE)Technical University of Munich(DE)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Histone Deacetylase Inhibitors Research, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → The target landscape of clinical kinase drugs(2017)850 cited
- → Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity(2016)181 cited
- → A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers(2016)176 cited
- → The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma(2021)61 cited
- → Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis(2018)41 cited
- → Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations(2017)14 cited
- → Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes(2017)7 cited
- → 34 AZACITIDINE DIRECTLY MODULATES FUNCTION OF MESENCHYMAL STROMAL CELLS TO ALTER BONE MARROW NICHE COMPOSTION AND SUPPRESS MALIGNANT HEMATOPOEITIC PROGENITORS IN MDS(2015)2 cited
- → Polycomb Protein RING1A Limits Differentiation in Myelodysplastic Syndromes(2017)
- → The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism(2019)